PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 74 filers reported holding PMV PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,297,293 | -1.9% | 6,563,077 | 0.0% | 0.86% | +15.1% |
| Q2 2023 | $41,084,862 | +31.2% | 6,563,077 | 0.0% | 0.74% | +21.0% |
| Q1 2023 | $31,305,877 | -45.2% | 6,563,077 | 0.0% | 0.62% | -43.7% |
| Q4 2022 | $57,098,770 | -26.9% | 6,563,077 | 0.0% | 1.09% | -24.7% |
| Q3 2022 | $78,101,000 | -16.5% | 6,563,077 | 0.0% | 1.45% | -14.5% |
| Q2 2022 | $93,524,000 | -34.5% | 6,563,077 | -4.3% | 1.70% | -26.8% |
| Q1 2022 | $142,730,000 | -15.7% | 6,855,423 | -6.5% | 2.31% | +6.3% |
| Q4 2021 | $169,333,000 | -22.5% | 7,330,423 | 0.0% | 2.18% | -9.3% |
| Q3 2021 | $218,447,000 | -12.8% | 7,330,423 | 0.0% | 2.40% | -5.2% |
| Q2 2021 | $250,407,000 | +3.9% | 7,330,423 | 0.0% | 2.53% | +12.4% |
| Q1 2021 | $241,098,000 | -46.5% | 7,330,423 | 0.0% | 2.25% | -42.9% |
| Q4 2020 | $450,894,000 | +73.3% | 7,330,423 | 0.0% | 3.95% | +20.6% |
| Q3 2020 | $260,230,000 | – | 7,330,423 | – | 3.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |